Last October Mirati Therapeutics announced the first clinical results of the phase I / II study on MRTX849 in patients with solid tumors expressing KRAS G12C mutations. According to Mirati, MRTX849 has demonstrated clinical activity, including objective responses, in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). MRTX849 by Mirati is undergoing phase I / II trials in patients with solid tumors expressing KRAS G12C mutations together with AMGN-510 by Amgen.
The marathon appears to have started in the pharmaceutical sector for non-small cell lung cancer (NSCLC). Here are some KRAS insights, that we consider extremely valuable.
For three decades, mutations in the KRAS pathway have been recognized as an important factor in oncology and, over the past year, both Amgen and Mirati have suggested being close rivalries.
Jefferies’ Michael Yee said that
“The first expected MRTX (Mirati’s mrtx849) data shown at high doses give some clear and early activities that are largely similar to the 2 readings that AMGN has reported on AMG-510 in recent months. Overall, we see no change in the thesis of AMGN and consensus expects the competition and the data in our view to state that the competitor is clearly not better or worse in any way. So, the two will go on and the expected competition will continue, but both seem active. “
However, there was a clear no to the Miratis MRTX849 from Sahm Adrangi’s team in Kerrisdale, saying
“The Mirati MRTX-849 KRAS inhibitor will likely fail as second-line monotherapy in the KRAS mutant NSCLC. There are few credible scientific reasons for trying to combine” 849 with inhibition of the checkpoint, and the attempt will almost certainly fail, given that KRAS mutant tumors are already quite susceptible to CPIs, and it will prove extraordinarily difficult to improve this effect. “
Reports also suggest that “MRTX-849 is a first generation KRAS inhibitor that will quickly become obsolete even in the unlikely scenario that it has been approved,” so if KRAS (which causes cancer) has found a cure to cure cancer it remains unscrupulous.
While Amgen’s AMG-510 and Mirati’s MRTX-849 really incited responses in patients with NSCLC, it is turning out to be certain that the response rate is lower, and the length of these responses is unfathomably fleeting. This makes market entry of medications as single treatment to be incredibly far-fetched, even in the second-line treatment.